GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Lamivudine and lamivudine/zidovudine

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

HIV and hepatitis-B lamivudine dosing differ. The single-agent and fixed-combination records must not be interchanged.

The preserved source page includes lamivudine and a zidovudine combination. Newly added adult single-agent and pediatric guidance are explicitly scoped; do not transfer single-agent dose changes to the fixed combination. NIH and the Southern African society use different renal approaches and alternatives.

Check source scope before reading a dose

NIH pediatric ARV guidance - renal and fixed-combination cautions

Product / population
Pediatric-source safety and formulation guidance; no pediatric numeric renal regimen imported
Renal method
CrCl mL/min as specified in pediatric source
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Professional

NIH pediatric ARV guidance - renal and fixed-combination cautions

Open original reference

NIH ClinicalInfo pediatric ARV panel · Pediatric-source safety and formulation guidance; no pediatric numeric renal regimen imported

Renal method: CrCl mL/min as specified in pediatric source
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Pediatric ARV guidance: lamivudine needs renal adjustment. Do not use lamivudine-containing fixed-dose tablets when CrCl <30 mL/min or on dialysis because individual component doses cannot be adjusted. With sustained CrCl 30-49, the guidance highlights increased exposure and monitoring for hematologic toxicity, potentially requiring a change from the combination.

This is a pediatric-source caution, not a numeric pediatric renal schedule. Adult dose tables elsewhere on this page must not be substituted. Epivir-HBV products have lower concentrations/strengths and are not interchangeable with HIV doses.

RDM30-110-lamivudine-lamivudineazt-1 · Source locator: NIH pediatric ARV guidance - renal and fixed-combination cautions; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/lamivudine
Retrieved
2026-09-05
Renal-function method
CrCl mL/min as specified in pediatric source
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
5237aba86fbc68ed8e39d8799abd019e1c595e0a6798aff54ac499034d2ecbe5

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=lamivudine-lamivudineazt&s1=RDM30-110-lamivudine-lamivudineazt&h1=ba4b630479c1e94e8a48936ac43d73a8606bbd53280184e2c8fc43bd5ed87f64